Jeffrey Humphrey, MD
CEO, Stealth Biotechnology Company

Dr. Jeffrey Humphrey is Chief Executive Officer of a biotechnology company currently in stealth mode. He was formerly Chief Medical Officer (CMO) of Magenta Therapeutics directing development of biologics for transplant conditioning. As CMO at Constellation Pharmaceuticals, acquired in 2021 by Morphosys, he directed development of drugs that modify epigenetic regulation of gene expression. As Chief Development Officer of Kyowa Kirin, he built the company’s US and EU clinical research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Crysvita®, Poteligeo®, Nourianz®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol-Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®).

Dr. Humphrey is a graduate of Harvard College and Case Western Reserve University School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the National Cancer Institute, with board certification in oncology.